Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, August 2008, p. 2996-2997, Vol. 52, No. 8
0066-4804/08/$08.00+0 doi:10.1128/AAC.00325-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
| LETTER TO THE EDITOR |

|
|
|---|
A total of 113 nonrepetitive ciprofloxacin-resistant E. coli clinical isolates were taken at random from the laboratory collections of four unrelated hospitals in northern and central Greece between 2006 and 2007 and analyzed for qnr genes. Ciprofloxacin MICs were estimated by the Etest (AB Biodisk, Solna, Sweden) and the agar dilution method according to Clinical and Laboratory Standards Institute (CLSI) guidelines (3) by using the breakpoints 1 and 4 µg/ml for susceptibility and resistance, respectively. E. coli ATCC 25922 was used as a control in all susceptibility assays; positive controls for the genes qnrA, qnrB, and qnrS were kindly provided by J. Sanchez-Cespedes. Susceptibilities to all antimicrobials tested were defined according to the CLSI interpretative criteria (3).
PCR was performed with primers amplifying all known qnr gene variants. The primer pair for the gene qnrA was 5'-AGAGGATTTCTCACGCCAGG-3' and 5'-CCAGGCACAGATCTTGAC-3' (yielding a 580-bp product), that for qnrB was 5'-GGGTATGGATATTATTGATAAAG-3' and 5'-CTAATCCGGCAGCACTATTA-3' (yielding a 264-bp product), and the primer pair for qnrS was 5'-GCAAGTTCATTGAACAGGGT-3' and 5'-TCTAAACCGTCGAGTTCGGC-3' (yielding a 428-bp product). The gene gyrA was amplified with primers 5'-TTAATGATTGCCGCCGTCGG-3' and 5'-TACACCGGTCAACATTGAGG-3' (yielding a 648-bp product) and parC was amplified with primers 5'-AAACCTGTTCAGCGCCGCATT-3' and 5'-GTGGTGCCGTTAAGCAAA-3' (yielding a 395-bp product) to evaluate possible coexisting chromosomal mutations. The corresponding specific PCR products were sequenced by LARK Technologies, Essex, United Kingdom.
For the qnr-positive isolates, synergy experiments were also performed using ciprofloxacin and the efflux pump inhibitor CCCP (carbonyl cyanide m-chlorophenylhydrazone) (8) to check the contribution of efflux pump overexpression to ciprofloxacin resistance. Pulsed-field gel electrophoresis (PFGE) analysis of XbaI-digested genomic DNA was performed, and the banding patterns of the strains were compared visually according to the criteria proposed by Tenover et al. (9). Filter mating experiments were performed with qnr-positive isolates by using E. coli 26R793 (lac negative and rifampin resistant) as the recipient. Transconjugants were selected on MacConkey agar plates containing 100 mg of rifampin/liter and 6 mg of nalidixic acid/liter, tested for qnr genes by PCR, and analyzed for plasmids by alkaline lysis.
Eleven of the 113 E. coli isolates (10%) derived from three independent hospitals in Thessaly (Larissa, central Greece) and Macedonia (Thessaloniki, northern Greece) and exhibiting nine unrelated PFGE strain patterns were qnr positive. The ciprofloxacin MICs for these isolates were 16 to 128 µg/ml; the characteristics of the isolates are presented in Table 1. One Qnr-positive isolate (isolate 3) was an extended-spectrum β-lactamase producer carrying the gene blaCTX-M-15. No synergy between CCCP and ciprofloxacin in any isolate was observed. Sequencing of the PCR products showed that all 11 isolates carried the allele qnrS1, that none carried qnrA or qnrB, and that all had the mutations in the genes gyrA and parC that commonly confer ciprofloxacin resistance on E. coli isolates (2, 4) (Table 1). Mating experiments revealed that qnrS1 gene-carrying plasmids of various molecular sizes in 5 of the 11 isolates were transferable to the susceptible host. Ciprofloxacin MICs for the transconjugants were 0.25 to 0.5 µg/ml, while the MIC for the susceptible E. coli recipient was 0.032 µg/ml.
|
View this table: [in a new window] |
TABLE 1. Characteristics of the 11 qnrS1-positive study isolates
|
In conclusion, qnr genes seem to be common in ciprofloxacin-resistant clinical E. coli isolates and may contribute to the alarming rates of quinolone resistance in Greece.
Published ahead of print on 19 May 2008. |
|
|---|
|
Olga Vasilaki
Department of Microbiology AHEPA University Hospital Thessaloniki, Greece
Eleni Ntokou
Danae Sofianou
Filanthi Frantzidou
Antonios N. Maniatis
| ||||||
| * Phone: (30) 2410 682929, Fax: (30) 2410 681570, E-mail: pournaras{at}med.uth.gr |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»